8 results about "Early onset" patented technology

The present disclosure provides methods for treating or managing fibromyalgia and its associated symptoms in a subject in need hereof characterized by an early onset of one or more of: (1) a reduction in widespread pain characterized by about 0.3 or more difference in the LS mean change in the NRS Pain Score; (2) a reduction in sleep disturbance characterized by about 2.9 or more difference in the LS Mean change in PROMIS Sleep Disturbance T-score; (3) a reduction in fatigue characterized by about 2.0 or more difference in the LS Mean change in PROMIS Fatigue T-score; or (4) an improved sleep quality characterized by about 0.5 or more difference in the LS Mean change in NRS Sleep Quality Score, each as compared to placebo, comprising administering to a subject in need thereof 2.8 mg or 5.6 mg cyclobenzaprine HCl once daily in one or more dosage units by transmucosal administration. The present disclosure also provides methods for preventing or avoiding one or more of a clinically meaningful change in mean weight, a clinically meaningful change in mean systolic blood pressure or mean diastolic blood pressure, or a decline in sexual functioning in conjunction with treating or managing fibromyalgia or its associated symptoms in a subject in need thereof, the treatment or management being characterized by the transmucosal administration of cyclobenzaprine HCl in one or more dosage units (e.g., a first dosage unit or a second dosage unit). The cyclobenzaprine HCl of these methods is in the form of a mannitol eutectic (e.g., a 75%±2% by weight cyclobenzaprine HCl and 25%±2% by weight β-mannitol eutectic) and the one or more dosage units further comprise a basifying agent.

Disclosed are methods, kits, and models for identifying early onset sepsis (EOS) in a subject based on the levels of at least three proteins selected from CRP, EBP, SAA1, LRG1, and SERPINA3 or RNAs encoding said proteins.

The present application relates to the technical field of pregnancy rate prediction, and particularly relates to a model establishment method and system for predicting pregnancy rate of early-onset ovarian dysfunction, which obtains clinical data of a patient, identifies four types of prediction key points, including basic physiological characteristics, ovarian reserve function, treatment intervention and pregnancy outcome correlation. When the total amount of key points exceeds a first threshold value, a dimensionality reduction improved feedforward neural network is constructed, and basic physiological characteristics and treatment intervention data are used as inputs to predict ovarian function and pregnancy outcome. When the number of key points is small, a graph neural network is used, a directed graph structure is constructed based on clustering and hierarchical relationship of each key point, and node state is dynamically updated based on basic physiological characteristics, so as to realize classification prediction of ovarian function and pregnancy risk, improve prediction accuracy and model interpretability, and provide personalized and intelligent decision support for fertility evaluation of POI patients.

Methods and kits are disclosed to detect the early onset, determine the risk and / or severity, diagnose, and determine the progression or regression of radiotherapy-associated neuronal damage derived from samples of a subject by quantifying one or more biomarkers at concentrations indicative of the condition. The one or more biomarkers comprise neurofilament light chain (NfL).

Disclosed herein are methods, devices, and systems for the enhanced monitoring of visual function via telemedicine to detect early onset of changes and abnormalities associated with disease. The systems include a cloud environment or neural network communicating various tests and images to a client device in which a user / patient is properly positioned to view a display of the client device, receive stimuli, and provide patient input which is evaluated in terms of timing and substance to generate a contrast-sensitivity map of a visual function for the patient. Various ocular tests are described for implementation in a new home-based computer environment rather than using expensive and specific medical equipment in a doctor's office.

The present invention provides a monoclonal antibody designed for the diagnosis and early detection of prostate cancer, particularly in relation to a monoclonal antibody developed to target the specificity of soluble ADAM9 variants (sADAM9v2) secreted in the vicinity of prostate cancer.